Efficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs

Journal of Medicinal Chemistry

Volumn 56, Issue 10, 2013, Pages 4104-4115

  Wolfe, Amanda L ^a   Duncan, Katharine K ^a   Parelkar, Nikhil K ^b   Brown, Douglas ^b   Vielhauer, George A ^b,c   Boger, Dale L ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUOCARMYCIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYCLIZATION; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR MEMBRANE; LEUKEMIA; MOUSE; NONHUMAN; REDUCTION; SURVIVOR;

ALKYLATION; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DNA; INDICATORS AND REAGENTS; INDOLES; LEUKEMIA L1210; MICE; PRODRUGS; PYRROLIDINONES; SPECTROPHOTOMETRY, ULTRAVIOLET; STEREOISOMERISM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878093139     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400413r     Document Type: Article

References (89)

1. Ichimura, M.; Ogawa, T.; Takahashi, K.; Kobayashi, E.; Kawamoto, I.; Yasuzawa, T.; Takahashi, I.; Nakano, H. Duocarmycin SA, A New Antitumor Antibiotic From Streptomyces sp J. Antibiot. 1990, 43, 1037-1038
2. Martin, D. G.; Biles, C.; Gerpheide, S. A.; Hanka, L. J.; Krueger, W. C.; McGovren, J. P.; Mizsak, S. A.; Neil, G. L.; Stewart, J. C.; Visser, J. CC-1065 (NSC 298223), A Potent New Antitumor Agent. Improved Production and Isolation, Characterization and Antitumor Activity J. Antibiot. 1981, 34, 1119-1125
3. Takahashi, I.; Takahashi, K.; Ichimura, M.; Morimoto, M.; Asano, K.; Kawamoto, I.; Tomita, F.; Nakano, H. Duocarmycin, A New Antitumor Antibiotic From Streptomyces J. Antibiot. 1988, 41, 1915-1917
4. Igarashi, Y.; Futamata, K.; Fujita, T.; Sekine, A.; Senda, H.; Naoki, H.; Furumai, T. Yatakemycin, A Novel Antifungal Antibiotic Produced by Streptomyces sp. TP-A0356 J. Antibiot. 2003, 56, 107-113
5. Boger, D. L.; Johnson, D. S.; Yun, W. (+)- and ent -(-)-Duocarmycin SA and (+)- and ent -(-)-N-BOC-DSA DNA Alkylation Properties. Alkylation Site Models That Accommodate the Offset AT-Rich Adenine N3 Alkylation Selectivity of the Enantiomeric Agents J. Am. Chem. Soc. 1994, 116, 1635-1656
6. Parrish, J. P.; Kastrinsky, D. B.; Wolkenberg, S. E.; Igarashi, Y.; Boger, D. L. DNA Alkylation Properties of Yatakemycin J. Am. Chem. Soc. 2003, 125, 10971-10976
7. Trzupek, J. D.; Gottesfeld, J. M.; Boger, D. L. Alkylation of Duplex DNA in Nucleosome Core Particles by Duocarmycin SA and Yatakemycin Nat. Chem. Biol. 2006, 2, 79-82
8. Tichenor, M. S.; MacMillan, K. S.; Trzupek, J. D.; Rayl, T. J.; Hwang, I.; Boger, D. L. Systematic Exploration of the Structural Features of Yatakemycin Impacting DNA Alkylation and Biological Activity J. Am. Chem. Soc. 2007, 129, 10858-10869
9. Hurley, L. H.; Lee, C.-S.; McGovren, J. P.; Warpehoski, M. A.; Mitchell, M. A.; Kelly, R. C.; Aristoff, P. A. Molecular Basis for Sequence-Specific DNA Alkylation by CC-1065 Biochemistry 1988, 27, 3886-3892
10. Boger, D. L.; Johnson, D. S.; Yun, W.; Tarby, C. M. Molecular Basis for Sequence Selective DNA Alkylation by (+)- and ent -(-)-CC-1065 and Related Agents: Alkylation Site Models that Accommodate the Offset AT-Rich Adenine N3 Alkylation Selectivity Bioorg. Med. Chem. 1994, 2, 115-135
11. Boger, D. L.; Munk, S. A.; Zarrinmayeh, H. (+)-CC-1065-DNA Alkylation: Key Studies Demonstrating a Noncovalent Binding Selectivity Contribution to the Alkylation Selectivity J. Am. Chem. Soc. 1991, 113, 3980-3983
12. Boger, D. L.; Zarrinmayeh, H.; Munk, S. A.; Kitos, P. A.; Suntornwat, O. Demonstration of a Pronounced Effect of Noncovalent Binding Selectivity on the (+)-CC-1065 DNA Alkylation and Identification of the Pharmacophore of the Alkylation Subunit Proc. Natl. Acad. Sci. U.S.A 1991, 88, 1431-1435
13. 3. Preparation of Key Partial Structures and Definition of an Additional Functional Role of the CC-1065 Central and Right-Hand Subunits J. Am. Chem. Soc. 1990, 112, 4623-4632
14. Boger, D. L.; Munk, S. A.; Zarrinmayeh, H. (+)-CC-1065 DNA Alkylation: Key Studies Demonstrating a Noncovalent Binding Selectivity Contribution to the Alkylation Selectivity J. Am. Chem. Soc. 1991, 113, 3980-3983
15. Boger, D. L.; Ishizaki, T.; Zarrinmayeh, H.; Munk, S. A.; Kitos, P. A.; Suntornwat, O. Duocarmycin-Pyrindamycin DNA Alkylation Properties and Identification, Synthesis, and Evaluation of Agents Incorporating the Pharmacophore of the Duocarmycin-Pyrindamycin Alkylation Subunit. Identification of the CC-1065 Duocarmycin Common Pharmacophore J. Am. Chem. Soc. 1990, 112, 8961-8971
16. Boger, D. L.; Ishizaki, T.; Zarrinmayeh, H. Isolation and Characterization of the Duocarmycin-Adenine DNA Adduct J. Am. Chem. Soc. 1991, 113, 6645-6649
17. Boger, D. L.; Yun, W.; Terashima, S.; Fukuda, Y.; Nakatani, K.; Kitos, P. A.; Jin, Q. DNA Alkylation Properties of the Duocarmycins: (+)-Duocarmycin A, epi -(+)-Duocarmycin A, ent -(-)-Duocarmycin A and epi, ent -(-)-Duocarmycin A Bioorg. Med. Chem. Lett. 1992, 2, 759-765
18. Boger, D. L.; Yun, W. Reversibility of the Duocarmycin A and SA DNA Alkylation Reaction J. Am. Chem. Soc. 1993, 115, 9872-9873
19. Boger, D. L.; Invergo, B. J.; Coleman, R. S.; Zarrinmayeh, H.; Kitos, P. A.; Thompson, S. C.; Leong, T.; McLaughlin, L. W. A Demonstration of the Intrinsic Importance of Stabilizing Hydrophobic Binding and Noncovalent van der Waals Contacts Dominant in the Noncovalent CC-1065/B-DNA Binding Chem.-Biol. Interact. 1990, 73, 29-52
20. Boger, D. L.; Johnson, D. S. CC-1065 and the Duocarmycins: Understanding Their Biological Function Through Mechanistic Studies Angew. Chem., Int. Ed. Engl. 1996, 35, 1438-1474
21. Boger, D. L. The Duocarmycins: Synthetic and Mechanistic Studies Acc. Chem. Res. 1995, 28, 20-29
22. Boger, D. L.; Johnson, D. S. CC-1065 and the Duocarmycins: Unraveling the Keys to a New Class of Naturally Derived DNA Alkylating Agents Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 3642-3649
23. Boger, D. L.; Garbaccio, R. M. Shape-Dependent Catalysis: Insights into the Source of Catalysis for the CC-1065 and Duocarmycin DNA Alkylation Reaction Acc. Chem. Res. 1999, 32, 1043-1052
24. Tichenor, M. S.; Boger, D. L. Yatakemycin: Total Synthesis, DNA Alkylation, and Biological Properties Natural Prod. Rep 2008, 25, 220-226
25. MacMillan, K. S.; Boger, D. L. Fundamental Relationships Between Structure, Reactivity, and Biological Activity for the Duocarmycins and CC-1065 J. Med. Chem. 2009, 52, 5771-5780
26. Searcey, M. Duocarmycins: Nature's Prodrugs? Curr. Pharm. Des 2002, 8, 1375-1389
27. Tse, W. C.; Boger, D. L. Sequence-Selective DNA Recognition: Natural Products and Nature's Lessons Chem. Biol. 2004, 11, 1607-1617
28. Boger, D. L.; Coleman, R. S. Total Synthesis of (+)-CC-1065 and ent -(-)-CC-1065 J. Am. Chem. Soc. 1988, 110, 1321-1323
29. 2 J. Am. Chem. Soc. 1988, 110, 4796-4807
30. Boger, D. L.; Machiya, K. Total Synthesis of (+)-Duocarmycin SA J. Am. Chem. Soc. 1992, 114, 10056-10058
31. Boger, D. L.; Machiya, K.; Hertzog, D. L.; Kitos, P. A.; Holmes, D. Total Synthesis and Preliminary Evaluation of (+)- and ent -(-)-Duocarmycin SA J. Am. Chem. Soc. 1993, 115, 9025-9036
32. Boger, D. L.; McKie, J. A.; Nishi, T.; Ogiku, T. Enantioselective Total Synthesis of (+)-Duocarmycin A, epi -(+)-Duocarmycin A, and Their Unnatural Enantiomers J. Am. Chem. Soc. 1996, 118, 2301-2302
33. Boger, D. L.; McKie, J. A.; Nishi, T.; Ogiku, T. Total Synthesis of (+)-Duocarmycin A and epi -(+)-Duocarmycin A and Their Unnatural Enantiomers: Assessment of Chemical and Biological Properties J. Am. Chem. Soc. 1997, 119, 311-325
34. Boger, D. L.; Boyce, C. W.; Garbaccio, R. M.; Goldberg, J. A. CC-1065 and the Duocarmycins: Synthetic Studies Chem. Rev. 1997, 97, 787-828
35. Tichenor, M. S.; Kastrinsky, D. B.; Boger, D. L. Total Synthesis, Structure Revision, and Absolute Configuration of (+)-Yatakemycin J. Am. Chem. Soc. 2004, 126, 8396-8398
36. Tichenor, M. S.; Trzupek, J. D.; Kastrinsky, D. B.; Shiga, F.; Hwang, I.; Boger, D. L. Asymmetric Total Synthesis of (+)- and ent -(-)-Yatakemycin and Duocarmycin SA. Evaluation of Yatakemycin Key Partial Structures and Its Unnatural Enantiomer J. Am. Chem. Soc. 2006, 128, 15683-15696
37. MacMillan, K. S.; Nguyen, T.; Hwang, I.; Boger, D. L. Total Synthesis and Evaluation of iso -Duocarmycin SA and iso -Yatakemycin J. Am. Chem. Soc. 2009, 131, 1187-1194
38. Boger, D. L.; Hertzog, D. L.; Bollinger, B.; Johnson, D. S.; Cai, H.; Goldberg, J.; Turnbull, P. Duocarmycin SA Shortened, Simplified, and Extended Agents: A Systematic Examination of the Role of the DNA Binding Subunit J. Am. Chem. Soc. 1997, 119, 4977-4986
39. Boger, D. L.; Bollinger, B.; Hertzog, D. L.; Johnson, D. S.; Cai, H.; Mesini, P.; Garbaccio, R. M.; Jin, Q.; Kitos, P. A. Reversed and Sandwiched Analogs of Duocarmycin SA: Establishment of the Origin of the Sequence-Selective Alkylation of DNA and New Insights into the Source of Catalysis J. Am. Chem. Soc. 1997, 119, 4987-4998
40. Boger, D. L.; Garbaccio, R. M. Catalysis of the CC-1065 and Duocarmycin DNA Alkylation Reaction: DNA Binding Induced Conformational Change in the Agent Results in Activation Bioorg. Med. Chem. 1997, 5, 263-276
41. 2: CC-1065 Functional Agents Incorporating the Equivalent 1,2,9,9a-Tetrahydrocyclopropa[1,2- c ]benz[1,2- e ]indol-4-one (CBI) Left-Hand Subunit J. Am. Chem. Soc. 1989, 111, 6461-6463
42. 2: Enhanced Functional Analogs of CC-1065 Incorporating the 1,2,9,9a-Tetrahydrocyclopropa[ c ]benz[ e ]indol-4-one (CBI) Left-Hand Subunit J. Org. Chem. 1990, 55, 5823-5832
43. 2: Enhanced Functional Analogs of (+)-CC-1065. A Critical Appraisal of a Proposed Relationship Between Electrophile Reactivity, DNA Binding Properties, and Cytotoxic Potency Tetrahedron Lett. 1990, 31, 793-796
44. Boger, D. L.; Ishizaki, T.; Zarrinmayeh, H.; Kitos, P. A.; Suntornwat, O. A Potent, Simple Derivative of an Analog of the CC-1065 Alkylation Subunit Bioorg. Med. Chem. Lett. 1991, 1, 55-58
45. Boger, D. L.; Munk, S. A. DNA Alkylation Properties of Enhanced Functional Analogs of CC-1065 Incorporating the 1,2,9,9a-Tetrahydrocyclopropa[1, 2- c ]benz[1,2- e ]indol-4-one (CBI) Alkylation Subunit J. Am. Chem. Soc. 1992, 114, 5487-5496
46. 2 Substituent: Validation of a Direct Relationship Between Solvolysis Chemical Stability and in vitro Biological Potency J. Am. Chem. Soc. 1994, 116, 5523-5524
47. 1: CC-1065 Analogs Containing Deep-Seated Modifications in the DNA Binding Subunit Bioorg. Med. Chem. 1995, 3, 761-775
48. Boger, D. L.; Yun, W. CBI-TMI: Synthesis and Evaluation of a Key Analog of the Duocarmycins. Validation of a Direct Relationship between Chemical Solvolytic Stability and Cytotoxic Potency and Confirmation of the Structural Features Responsible for the Distinguishing Behavior of Enantiomeric Pairs of Agents J. Am. Chem. Soc. 1994, 116, 7996-8006
49. Parrish, J. P.; Katrinsky, D. B.; Stauffer, F.; Hedrick, M. P.; Hwang, I.; Boger, D. L. Establishment of Substituent Effects in the DNA Binding Subunit of CBI Analogues of the Duocarmycins and CC-1065 Bioorg. Med. Chem. 2003, 11, 3815-3838
50. Boger, D. L.; Wysocki, R. J.; Ishizaki, T. Synthesis of N-(Phenylsulfonyl)-CI, N-(tert-Butyloxy carbonyl-CI, CI-CDPI1, and CI-CDPI2: CC-1065 Functional Analogs Incorporating the Parent 1,2,7,7a- Tetrahydrocycloprop[1,2- c ]indol-4-one (CI) Left-Hand Subunit J. Am. Chem. Soc. 1990, 112, 5230-5240
51. Boger, D. L.; Yun, W.; Teegarden, B. R. An Improved Synthesis of 1,2,9,9a-Tetrahydrocyclopropa[ c ]benz[ e ]indol-4-one (CBI): A Simplified Analog of the CC-1065 Alkylation Subunit J. Org. Chem. 1992, 57, 2873-2876
52. Boger, D. L.; McKie, J. A. An Efficient Synthesis of 1,2,9,9a- Tetrahydrocyclopropa[ c ]benz[ e ]indol-4-one (CBI): An Enhanced and Simplified Analog of the CC-1065 and Duocarmycin Alkylation Subunits J. Org. Chem. 1995, 60, 1271-1275
53. Boger, D. L.; McKie, J. A.; Boyce, C. W. Asymmetric Synthesis of the 1,2,9,9a-Tetrahydrocyclopropa[ c ]benz[ e ]indol-4-one (CBI) Alkylation Subunit of CC-1065 and Duocarmycin Analogues Synlett 1997, 515-517
54. Kastrinsky, D. B.; Boger, D. L. Effective Asymmetric Synthesis of 1,2,9,9a-Tetrahydrocyclopropa[ e ]benz[ e ]indol-4-one (CBI) J. Org. Chem. 2004, 69, 2284-2289
55. Lajiness, J. P.; Boger, D. L. Asymmetric Synthesis of 1,2,9,9a-Tetrahydrocyclopropa[ c ]benz[ e ]indol-4-one (CBI) J. Org. Chem. 2010, 76, 583-587
56. Drost, K. J.; Cava, M. P. A Photochemically Based Synthesis of the Benzannelated Analog of the CC-1065 A Unit J. Org. Chem. 1991, 56, 2240-2244
57. Aristoff, P. A.; Johnson, P. D. Synthesis of CBI-PDE-I-Dimer, the Benzannelated Analog of CC-1065 J. Org. Chem. 1992, 57, 6234-6239
58. Mohamadi, F.; Speez, M. M.; Staten, G. S.; Marder, P.; Kipka, J. K.; Johnson, D. A.; Boger, D. L.; Zarrinmayeh, H. Total Synthesis and Biological Properties of Novel Antineoplastic (Chloromethyl)furanoindolines. An Asymmetric Hydroboration Mediated Synthesis of the Alkylation Subunits J. Med. Chem. 1994, 37, 232-239
59. Ling, L.; Xie, Y.; Lown, J. W. A Practical Route to Optically Active CBI, A Potent Analog of the CC-1065 Alkylation Subunit Heterocycl. Commun. 1997, 3, 405-408
60. Boger, D. L.; Yun, W.; Han, N. 1,2,9,9a-Tetrahydrocyclopropa[ c ]benz[ e ]indol-4-one (CBI) Analogs of CC-1065 and the Duocarmycins: Synthesis and Evaluation Bioorg. Med. Chem. 1995, 3, 1429-1453
61. 2: An Enhanced Functional Analog of CC-1065 Bioorg. Med. Chem. Lett. 1991, 1, 115-120
62. Li, L.; DeKoning, T. F.; Kelly, R. C.; Krueger, W. C.; McGovren, J. P.; Padbury, G. E.; Petzold, G. L.; Wallace, T. L.; Ouding, R. J.; Prairie, M. D.; Gebhard, I. Cytotoxicity and Antitumor Activity of Carzelesin, a Prodrug Cyclopropylpyrroloindole Analogue Cancer Res. 1992, 52, 4904-4913
63. van Tellingen, O.; Nooijen, W. J.; Schaaf, L. J.; van der Valk, M.; van Asperen, J.; Henrar, R. E. C.; Beijnen, J H. Comparative Pharmacology of the Novel Cyclopropylpyrroloindole-Prodrug Carzelesin in Mice, Rats, and Humans Cancer Res. 1998, 58, 2410-2416
64. Kobayashi, E.; Okamoto, A.; Asada, M.; Okabe, M.; Nagamura, S.; Asai, A.; Saito, H.; Gomi, K.; Hirata, T. Characteristics of Antitumor Activity of KW-2189, A Novel Water-Soluble Derivative of Duocarmycin, Against Murine and Human Tumors Cancer Res. 1994, 54, 2404-2410
65. Nagamura, S.; Kanda, Y.; Kobayashi, E.; Gomi, K.; Saito, H. Synthesis and Antitumor Activity of Duocarmycin Derivatives Chem. Pharm. Bull. 1995, 43, 1530-1535
66. Boger, D. L.; Boyce, C. W.; Garbaccio, R. M.; Searcey, M.; Jin, Q. CBI Prodrug Analogs of CC-1065 and the Duocarmycins Synthesis 1999, 1505-1509
67. Wang, Y.; Li, L.; Tian, Z.; Jiang, W.; Larrick, J. Synthesis and Antitumor Activity of CBI-Bearing Ester and Carbamate Prodrugs of CC-1065 Bioorg. Med. Chem. 2006, 14, 7854-7861
68. Li, L. S.; Sinha, S. C. Studies Toward the Duocarmycin Prodrugs for the Antibody Prodrug Therapy Approach Tetrahedron Lett. 2009, 50, 2932-2935
69. Wolfe, A. L.; Duncan, K. K.; Parelkar, N. K.; Weir, S. J.; Vielhauer, G. A.; Boger, D. L. A Novel, Unusually Efficacious Duocarmycin Carbamate Prodrug that Releases No Residual Byproduct J. Med. Chem. 2012, 55, 5878-5886
70. Tietze, L. F.; Lieb, M.; Herzig, T.; Haunert, F.; Schuberth, I. A Strategy for Tumor-Selective Chemotherapy by Enzymatic Liberation of seco-duocarmycin SA-derivatives from Nontoxic Prodrugs Bioorg. Med. Chem. 2001, 9, 1929-1939
71. Tietze, L. F.; Major, F.; Schuberth, I. Antitumor Agents: Development of Highly Potent Glycosidic Duocarmycin Analogues for Selective Cancer Therapy Angew. Chem., Int. Ed. 2006, 45, 6574-6577
72. Tietze, L. F.; Schuster, H. J.; Schmuck, K.; Schuberth, I.; Alves, F. Duocarmycin-based Prodrugs for Cancer Prodrug Monotherapy Bioorg. Med. Chem. 2008, 16, 6312-6318
73. Hay, M. P.; Anderson, R. F.; Ferry, D. M.; Wilson, W. R.; Denny, W. A. Synthesis and Evaluation of Nitroheterocyclic Carbamate Prodrugs for Use with Nitroreductase-Mediated Gene-Directed Enzyme Prodrug Therapy J. Med. Chem. 2003, 46, 5533-5545
74. Hay, M. P.; Sykes, B. M.; Denny, W. A.; Wilson, W. R. A 2-Nitroimidazole Carbamate Prodrug of 5-Amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl) carbonyl]-1,2-dihydro-3 H -benz[ e ]indole (Amino-seco-CBI-TMI) for Use With ADEPT and GDEPT Bioorg. Med. Chem. Lett. 1999, 9, 2237-2242
75. Tercel, M.; Atwell, G. J.; Yang, S.; Ashoorzadeh, A.; Stevenson, R. J.; Botting, K. J.; Gu, Y.; Mehta, S. Y.; Denny, W. A.; Wilson, W. R.; Pruijn, F. B. Selective Treatment of Hypoxic Tumor Cells In Vivo: Phosphate Pre-Prodrugs of Nitro Analogues of the Duocarmycins Angew. Chem., Int. Ed. 2011, 50, 2606-2609
76. Townes, H.; Summerville, K.; Purnell, B.; Hooker, M.; Madsen, E.; Hudson, S.; Lee, M. Investigation of a Novel Reductively-Activatable Anticancer Prodrug of seco -CBI-TMI, an Analog of Duocarmycin SA Med. Chem. Res. 2002, 11, 248-253
77. Boger, D. L.; Garbaccio, R. M. A Novel Class of CC-1065 and Duocarmycin Analogues Subject to Mitomycin-Related Reductive Activation J. Org. Chem. 1999, 64, 8350-8362
78. Zhao, R. H.; Erickson, H. K.; Leece, B. A.; Reid, E. E.; Goldmacher, V. S.; Lambert, J. M.; Chari, R. V. J. Synthesis and Biological Evaluation of Antibody Conjugates of Phosphate Prodrugs of Cytotoxic DNA Alkylators for the Targeted Treatment of Cancer J. Med. Chem. 2012, 55, 766-782
79. Pors, K.; Loadman, P. M.; Shnyder, S. D.; Sutherland, M.; Sheldrake, H. M.; Guino, M.; Kiakos, K.; Hartley, J. A.; Searcey, M.; Patterson, L. H. Modification of the Duocarmycin Pharmacophore Enables CYP1A1 Targeting for Biological Activity Chem. Commun. 2011, 47, 12062-12064
80. Wolkenberg, S. E.; Boger, D. L. Mechanisms of in situ Activation for DNA Targeting Antitumor Agents Chem. Rev. 2002, 102, 2477-2495
81. Jin, W.; Trzupek, J. D.; Rayl, T. J.; Broward, M. A.; Vielhauer, G. A.; Weir, S. J.; Hwang, I.; Boger, D. L. A Unique Class of Duocarmycin and CC-1065 Analogues Subject to Reductive Activation J. Am. Chem. Soc. 2007, 129, 15391-15397
82. Lajiness, J. P.; Robertson, W. M.; Dunwiddie, I.; Broward, M. A.; Vielhauer, G. A.; Weir, S. J.; Boger, D. L. Design, Synthesis, and Evaluation of Duocarmycin O -Amino Phenol Prodrugs Subject to Tunable Reductive Activation J. Med. Chem. 2010, 53, 7731-7738
83. Ahmad, S.; Okine, L.; Le, B.; Najarian, P.; Vistica, D. T. Elevation of Glutathione in Phenylalanine Mustard-resistant Murine L1210 Leukemia Cells J. Biol. Chem. 1987, 262, 15048-15053
84. Balendiran, G. K.; Dabur, R.; Fraser, D. The Role of Glutathione in Cancer Cell Biochem. Func 2004, 22, 343-352
85. Paz, M. M; Hopkins, P. B. DNA-DNA Interstrand Crosslinking by FR66979: Intermediates in the Activation Cascade J. Am. Chem. Soc. 1997, 119, 5999-6005
86. Williams, R. M.; Rajski, S. R.; Rollins, S. B. FR 900482, A Close Cousin of Mitomycin C that Exploits Mitosene-based DNA Crosslinking Chem. Biol. 1997, 4, 127-137
87. Tepe, J. J.; Kosogof, C.; Williams, R. M. DNA Interstrand Cross-link Formation by Reductive Activation of Dehydropyrrolizidine Progenitors Tetrahedron 2002, 58, 3553-3559
88. Boger, D. L.; Munk, S. A.; Zarrinmayeh, H.; Ishizaki, T.; Haught, J.; Bina, M. An Alternative and Convenient Strategy for Generation of Substantial Quantities of Singly 5′-P32-End-Labeled Double-Stranded DNA for Binding Studies. Development of a Protocol for Examination of Functional Features of (+)-CC-1065 and the Duocarmycins That Contribute to Their Sequence-Selective DNA Alkylation Properties Tetrahedron 1991, 47, 2661-2682
89. Boger, D. L.; Fink, B. E.; Brunette, S. R.; Tse, W. C.; Hedrick, M. P. A Simple High-Resolution Method for Establishing DNA Binding Affinity and Sequence Selectivity J. Am. Chem. Soc. 2001, 123, 5878-5891